CY1124890T1 - Συστηματα και μεθοδοι χορηγησης φαρμακων για θεραπεια καρκινου της ουροδοχου κυστης που περιλαμβανουν οξαλιπλατινη - Google Patents
Συστηματα και μεθοδοι χορηγησης φαρμακων για θεραπεια καρκινου της ουροδοχου κυστης που περιλαμβανουν οξαλιπλατινηInfo
- Publication number
- CY1124890T1 CY1124890T1 CY20221100014T CY221100014T CY1124890T1 CY 1124890 T1 CY1124890 T1 CY 1124890T1 CY 20221100014 T CY20221100014 T CY 20221100014T CY 221100014 T CY221100014 T CY 221100014T CY 1124890 T1 CY1124890 T1 CY 1124890T1
- Authority
- CY
- Cyprus
- Prior art keywords
- oxaliplatin
- bladder
- treatment
- methods
- drug delivery
- Prior art date
Links
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 title abstract 7
- 229960001756 oxaliplatin Drugs 0.000 title abstract 7
- 206010005003 Bladder cancer Diseases 0.000 title abstract 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 title abstract 2
- 238000012377 drug delivery Methods 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 201000005112 urinary bladder cancer Diseases 0.000 title abstract 2
- 206010011732 Cyst Diseases 0.000 abstract 1
- 210000005068 bladder tissue Anatomy 0.000 abstract 1
- 208000031513 cyst Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000002459 sustained effect Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 238000011200 topical administration Methods 0.000 abstract 1
- 230000002485 urinary effect Effects 0.000 abstract 1
- 210000002700 urine Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
- A61M31/002—Devices for releasing a drug at a continuous and controlled rate for a prolonged period of time
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/04—General characteristics of the apparatus implanted
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2210/00—Anatomical parts of the body
- A61M2210/10—Trunk
- A61M2210/1078—Urinary tract
- A61M2210/1085—Bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2210/00—Anatomical parts of the body
- A61M2210/10—Trunk
- A61M2210/1078—Urinary tract
- A61M2210/1089—Urethra
- A61M2210/1096—Male
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2210/00—Anatomical parts of the body
- A61M2210/16—Male reproductive, genital organs
- A61M2210/166—Prostate
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Molecular Biology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nanotechnology (AREA)
Abstract
Μέθοδοι, συσκευές και φάρμακα που περιλαμβάνουν οξαλιπλατίνη παρέχονται για χρήση στη θεραπεία του καρκίνου της ουροδόχου κύστης με τοπική χορήγηση οξαλιπλατίνης στην ουροδόχο κύστη ενός ασθενούς για την επίτευξη μιας παρατεταμένης συγκέντρωσης οξαλιπλατίνης στα ούρα στην ουροδόχο κύστη επαρκή για την παραγωγή θεραπευτικής συγκέντρωσης οξαλιπλατίνης στον ιστό της ουροδόχου κύστης. Η οξαλιπλατίνη μπορεί να χορηγηθεί στην ουροδόχο κύστη από μια συσκευή ενδοκυστικής χορήγησης φαρμάκου που έχει εισαχθεί στην ουροδόχο κύστη, όπου η συσκευή απελευθερώνει συνεχώς την οξαλιπλατίνη στα ούρα στην ουροδόχο κύστη για μια εκτεταμένη περίοδο ωρών ή ημερών.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261696027P | 2012-08-31 | 2012-08-31 | |
| PCT/US2013/057836 WO2014036555A1 (en) | 2012-08-31 | 2013-09-03 | Drug delivery systems and methods for treatment of bladder cancer comprising oxaliplatin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1124890T1 true CY1124890T1 (el) | 2023-01-05 |
Family
ID=49226511
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20221100014T CY1124890T1 (el) | 2012-08-31 | 2022-01-05 | Συστηματα και μεθοδοι χορηγησης φαρμακων για θεραπεια καρκινου της ουροδοχου κυστης που περιλαμβανουν οξαλιπλατινη |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US10543346B2 (el) |
| EP (1) | EP2890384B1 (el) |
| JP (1) | JP6463266B2 (el) |
| KR (1) | KR102157548B1 (el) |
| CN (1) | CN104640549B (el) |
| AU (1) | AU2013308464B2 (el) |
| BR (1) | BR112015003836A2 (el) |
| CA (1) | CA2882319C (el) |
| CY (1) | CY1124890T1 (el) |
| DK (1) | DK2890384T3 (el) |
| ES (1) | ES2902833T3 (el) |
| HR (1) | HRP20211921T1 (el) |
| HU (1) | HUE056976T2 (el) |
| IL (1) | IL237281B (el) |
| IN (1) | IN2015DN01561A (el) |
| LT (1) | LT2890384T (el) |
| MX (1) | MX365688B (el) |
| PL (1) | PL2890384T3 (el) |
| PT (1) | PT2890384T (el) |
| RS (1) | RS62875B1 (el) |
| RU (1) | RU2657591C2 (el) |
| SG (1) | SG11201501424SA (el) |
| SI (1) | SI2890384T1 (el) |
| WO (1) | WO2014036555A1 (el) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8721621B2 (en) | 2009-09-10 | 2014-05-13 | Taris Biomedical, Inc. | Systems and methods for deploying devices to genitourinary sites |
| JP6309009B2 (ja) | 2012-08-31 | 2018-04-11 | タリス バイオメディカル エルエルシー | 前立腺の治療のための薬物送達システム及び方法 |
| SG11201610656QA (en) | 2014-06-23 | 2017-01-27 | Placon Therapeutics Inc | Platinum compounds, compositions, and uses thereof |
| AU2016289856B2 (en) | 2015-07-07 | 2020-11-26 | H. Lundbeck A/S | PDE9 inhibitors with imidazo triazinone backbone and imidazo pyrazinone backbone for treatment of peripheral diseases |
| JP2019514970A (ja) * | 2016-05-06 | 2019-06-06 | タリス バイオメディカル エルエルシー | 下部尿路上皮がんを処置する方法 |
| CN109475556A (zh) | 2016-07-06 | 2019-03-15 | 伊马拉公司 | 用于治疗外周疾病的pde9抑制剂 |
| MA48793A (fr) | 2017-05-26 | 2020-04-08 | Imara Inc | Procédés de fabrication et d'utilisation d'inhibiteurs de pde9 |
| WO2019023388A1 (en) | 2017-07-25 | 2019-01-31 | Taris Biomedical Llc | METHODS OF TREATING TUMOR METASTASIS |
| IL302714A (en) | 2017-11-08 | 2023-07-01 | Taris Biomedical Llc | Treatment methods and maintenance treatment for bladder cancer using gemcitabine |
| BR122023022641A2 (pt) | 2018-05-25 | 2024-02-20 | Imara Inc. | Forma cristalina de monoidrato, composição farmacêutica compreendendo a mesma, método de inibição da atividade de pde9 em um paciente e processo para preparar a forma de monoidrato 2 |
| JP2021532155A (ja) * | 2018-08-01 | 2021-11-25 | タリス バイオメディカル エルエルシー | トロスピウムを使用した過活動膀胱の治療方法 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6171298B1 (en) | 1996-05-03 | 2001-01-09 | Situs Corporation | Intravesical infuser |
| CA2503193A1 (en) | 2002-10-22 | 2004-05-06 | The Biomerix Corporation | Method and system for intravesicular delivery of therapeutic agents |
| RU2006146623A (ru) * | 2004-06-03 | 2008-07-20 | Ф.Хоффманн-Ля Рош Аг (Ch) | Лечение оксалиплатином и ингибитором рецептора эпидермального фактора роста (egfr) |
| US8361490B2 (en) | 2004-09-16 | 2013-01-29 | Theracoat Ltd. | Biocompatible drug delivery apparatus and methods |
| US20100003297A1 (en) | 2005-08-11 | 2010-01-07 | Massachusetts Institute Of Technology | Implantable Drug Delivery Device and Methods of Treating Male Genitourinary and Surrounding Tissues |
| CA2618349C (en) | 2005-08-11 | 2016-05-31 | Massachusetts Institute Of Technology | Intravesical drug delivery device and method |
| BRPI0820800B8 (pt) | 2007-12-11 | 2021-06-22 | Massachusetts Inst Technology | dispositivo médico implantável para liberação controlada de droga |
| KR20100131471A (ko) | 2008-04-04 | 2010-12-15 | 리펠라 파마슈티칼즈, 인코포레이티드. | 리포솜 보톨리눔 독소를 이용한 방광기능장애의 치료 |
| JP2011528275A (ja) * | 2008-07-17 | 2011-11-17 | ミセル テクノロジーズ，インク． | 薬物送達医療デバイス |
| DK2445570T3 (da) * | 2009-06-26 | 2013-02-25 | Taris Biomedical Inc | Implanterbare lægemiddelafgivelsesindretninger samt fremgangsmåder til deres fremstilling |
| US9017312B2 (en) | 2009-09-10 | 2015-04-28 | Taris Biomedical Llc | Implantable device for controlled drug delivery |
| HUE053888T2 (hu) | 2009-12-17 | 2021-07-28 | Taris Biomedical Llc | Intravezikálisan tolerálható beültethetõ eszköz |
| US8690840B2 (en) | 2010-10-06 | 2014-04-08 | Taris Biomedical, Inc. | Time-selective bioresorbable or collapsible drug delivery systems and methods |
| WO2012065044A2 (en) | 2010-11-12 | 2012-05-18 | Purdue Research Foundation | Treating bladder tumor cells using fibronectin attachment protein as a target |
| WO2012096985A1 (en) | 2011-01-10 | 2012-07-19 | Taris Biomedical, Inc. | Lidocaine regimen for the use of sustained treatment of bladder pain and irritative voiding |
| ES2637388T3 (es) * | 2011-02-04 | 2017-10-13 | Taris Biomedical, Inc. | Dispositivo implantable para la liberación controlada de un fármaco de baja solubilidad |
| JP6309009B2 (ja) | 2012-08-31 | 2018-04-11 | タリス バイオメディカル エルエルシー | 前立腺の治療のための薬物送達システム及び方法 |
| WO2014047221A1 (en) | 2012-09-18 | 2014-03-27 | Taris Biomedical, Inc. | Drug delivery systems and methods for treatment of bladder voiding dysfunction|and other lower urinary tract disorders by using trospium |
| KR102293280B1 (ko) | 2013-03-15 | 2021-08-23 | 타리스 바이오메디컬 엘엘씨 | 약물-투과성 구성요소를 가지는 약물 전달 장치 및 방법 |
| KR102503010B1 (ko) | 2013-08-19 | 2023-02-24 | 타리스 바이오메디컬 엘엘씨 | 다중 유닛 약물 전달 장치 및 방법 |
-
2013
- 2013-09-03 PT PT137658399T patent/PT2890384T/pt unknown
- 2013-09-03 DK DK13765839.9T patent/DK2890384T3/da active
- 2013-09-03 ES ES13765839T patent/ES2902833T3/es active Active
- 2013-09-03 CN CN201380044244.3A patent/CN104640549B/zh not_active Expired - Fee Related
- 2013-09-03 CA CA2882319A patent/CA2882319C/en active Active
- 2013-09-03 PL PL13765839T patent/PL2890384T3/pl unknown
- 2013-09-03 RU RU2015109296A patent/RU2657591C2/ru active
- 2013-09-03 SI SI201331961T patent/SI2890384T1/sl unknown
- 2013-09-03 EP EP13765839.9A patent/EP2890384B1/en active Active
- 2013-09-03 JP JP2015530138A patent/JP6463266B2/ja not_active Expired - Fee Related
- 2013-09-03 BR BR112015003836A patent/BR112015003836A2/pt not_active Application Discontinuation
- 2013-09-03 HR HRP20211921TT patent/HRP20211921T1/hr unknown
- 2013-09-03 SG SG11201501424SA patent/SG11201501424SA/en unknown
- 2013-09-03 AU AU2013308464A patent/AU2013308464B2/en not_active Ceased
- 2013-09-03 RS RS20220054A patent/RS62875B1/sr unknown
- 2013-09-03 MX MX2015002325A patent/MX365688B/es active IP Right Grant
- 2013-09-03 WO PCT/US2013/057836 patent/WO2014036555A1/en active Application Filing
- 2013-09-03 KR KR1020157007349A patent/KR102157548B1/ko active IP Right Grant
- 2013-09-03 HU HUE13765839A patent/HUE056976T2/hu unknown
- 2013-09-03 LT LTEPPCT/US2013/057836T patent/LT2890384T/lt unknown
-
2015
- 2015-02-17 IL IL237281A patent/IL237281B/en active IP Right Grant
- 2015-02-23 US US14/628,900 patent/US10543346B2/en not_active Expired - Fee Related
- 2015-02-25 IN IN1561DEN2015 patent/IN2015DN01561A/en unknown
-
2019
- 2019-12-16 US US16/715,857 patent/US11007355B2/en active Active
-
2022
- 2022-01-05 CY CY20221100014T patent/CY1124890T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1124890T1 (el) | Συστηματα και μεθοδοι χορηγησης φαρμακων για θεραπεια καρκινου της ουροδοχου κυστης που περιλαμβανουν οξαλιπλατινη | |
| MX2020002465A (es) | Sistemas de administracion de farmaco y metodos para el tratamiento de la disfuncion miccional de la vejiga y otros transtornos del tracto urinario inferior. | |
| MX367070B (es) | Sistemas de administracion de farmaco y metodos para el tratamiento de la prostata. | |
| MX2021004546A (es) | Composiciones de suministro de farmaco implantables y metodos de uso de las mismas. | |
| NZ720736A (en) | Antibody drug conjugates (adcs) with kinesin spindel protein (ksp) | |
| CY1116727T1 (el) | Θεραπεια πολλαπλης σκληρυνσης me laquinimod | |
| MX2016011333A (es) | Sistemas de administracion de farmaco y metodo para el tratamiento de cancer de vejiga con gemcitabina. | |
| ECSP12011716A (es) | (heteroarilmetil)tiohidantoínas sustituidas como drogas anticáncer | |
| MX2017017138A (es) | Conjugados homogeneos especificos de sitio con inhibidores de ksp. | |
| BR112013007681A2 (pt) | uso terapêutico de um agonista trl e terapia de combinação | |
| EA201100335A8 (ru) | Производные пурина для применения при лечении связанных с fab заболеваний | |
| EA201591679A1 (ru) | Способ нетоксического лечения абстиненции, вызванной лекарственным средством | |
| MX352824B (es) | Uso de levocetirizina y montelukast en el tratamiento de influenza, resfriado común e inflamación. | |
| MX2013008175A (es) | Composiciones farmacéuticas para suministro tópico de fotosensibilizadores y usos de los mismos. | |
| CY1117831T1 (el) | Θεραπεια συνδυασμου για τη θεραπευτικη αγωγη του καρκινου του μαστου | |
| EA201391689A1 (ru) | Система доставки лекарственного средства | |
| MX2015011775A (es) | Uso de levocetirizina y montelukast en el tratamiento de anafilaxis. | |
| MX2013006319A (es) | Composiciones y metodos para tratar el cancer usando un inhibidor de pi3k y un inhibidor de mek. | |
| AR079000A1 (es) | Terapia anticancerosa dirigida a celulas madre cancerosas resistentes a las drogas | |
| CR20110687A (es) | Procedimientos de uso del factor liberador de corticotropina para el tratamiento de cancer | |
| UA113183C2 (xx) | Спосіб лікування адикції | |
| EA201491836A1 (ru) | Способы лечения рака с использованием ингибитора pi3k и ингибитора mek | |
| EA201992762A1 (ru) | Трансмукозальные устройства для доставки лекарств для применения при облегчении хронической боли | |
| Barsotti | CMV lung infection, bladder infection and erythematous rash: 3 case reports | |
| EA201590325A1 (ru) | Улучшенные способы лечения рака с пониженной почечной токсичностью |